SCHEMBL5083765

SCHEMBL5083765

c1ccc(Oc2ccc3ccc(-c4nn(C5CC(CN6CCC6)C5)c5ncncc45)cc3n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 11/20 0.39
INSR P06213 5/20 0.39
KDR P35968 4/20 0.39
EGFR P00533 2/20 0.39
CYP3A4 P08684 1/20 0.39
BTK Q06187 7/20 0.37
LCK P06239 4/20 0.37
LYN P07948 4/20 0.37
FLT3 P36888 4/20 0.37
KIT P10721 3/20 0.37
FGFR1 P11362 3/20 0.37
FLT1 P17948 3/20 0.37
FLT4 P35916 3/20 0.37
ERBB4 Q15303 3/20 0.37
SRC P12931 2/20 0.37
RET P07949 2/20 0.37
PIK3CG P48736 2/20 0.37
ERBB2 P04626 2/20 0.37
PDPK1 O15530 1/20 0.37
MET P08581 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5138051 0.88 IGF1R (0.35) IGF1RINSRKDREGFRBTK
SCHEMBL5142261 0.86 IGF1R (0.38) IGF1RINSRKDREGFRCYP3A4
SCHEMBL396331 0.86 BTK (0.54) IGF1RINSRKDREGFRBTK
SCHEMBL5138247 0.79 IGF1R (0.42) IGF1RINSRKDREGFRCYP3A4
SCHEMBL5138853 0.77 IGF1R (0.43) IGF1RINSRKDREGFRBTK
SCHEMBL400678 0.76 BTK (0.50) IGF1RINSRKDREGFRBTK
SCHEMBL402558 0.76 BTK (0.46) IGF1RINSRKDREGFRBTK
SCHEMBL400064 0.75 IGF1R (0.68) IGF1RINSRKDREGFRBTK
SCHEMBL5138129 0.74 IGF1R (0.46) IGF1RINSRKDREGFRBTK
SCHEMBL5085578 0.73 IGF1R (0.55) IGF1RINSRKDREGFRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979002-A2 COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT OSI Pharmaceuticals, Inc. (US) 2008-10-15 EP disclosed
WO-2008076143-A1 COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT OSI PHARMACEUTICALS, INC. (US) 2008-06-26 WO disclosed
WO-2007075554-A2 COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT OSI PHARMACEUTICALS, INC. (US) 2007-07-05 WO disclosed